- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 939
- Incorporated in 1998
- Headquartered in Warren, New Jersey
- https://www.ptcbio.com
IPO : June 20, 2013
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Address
100 Corporate Court
SOUTH PLAINFIELD, NJ 07080-2449
United States
SOUTH PLAINFIELD, NJ 07080-2449
United States
Website links www.ptcbio.com
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -205.62% | -77.28% |
| Operating margin | -120.09% | -78.97% |
| EBITD margin | - | -71.01% |
| Return on average assets | - | -91.70% |
| Return on average equity | - | - |
| Employees | 123 |
